Consorcio Hospital General Universitario De Valencia

At Consorcio Hospital General Universitario De Valencia, the oncology program is centered on a broad range of cancer studies, with trials exploring both treatment effectiveness and ways to improve long-term outcomes for people with solid tumors.

• Breast cancer research, including early-stage disease and HR-positive/HER2-negative breast cancer, is focused on follow-up, relapse patterns, and comparing treatment strategies for advanced disease.
• Studies in lung cancer cover metastatic non-small-cell lung cancer and RET fusion-positive NSCLC, aiming to test new targeted and cell-based therapies that may improve survival and disease control.
• Trials in head and neck squamous cell carcinoma, advanced melanoma, and gastrointestinal stromal tumor are evaluating novel combinations and therapeutic approaches for difficult-to-treat cancers.

This work reflects a strong focus on oncology innovation, from testing new immunotherapy and targeted therapy options to measuring how well current treatments prevent recurrence or extend survival.

The site also contributes to research in digestive system diseases, especially cancers and liver conditions, with trials designed to refine adjuvant treatment and assess whether new therapies can improve clinical outcomes.

• Localised colon cancer studies are examining whether more intensive postoperative treatment can improve recurrence-free survival and support better disease control.
• Research in gastrointestinal stromal tumor is looking at ways to reduce the risk of recurrence in patients who remain at high risk after standard treatment.
• The program includes non-alcoholic steatohepatitis studies that aim to improve liver inflammation and fibrosis while also assessing treatment safety over time.

These trials combine cancer care and liver disease research, showing interest in both treatment effectiveness and longer-term disease management.

Within skin and connective tissue diseases, the research portfolio includes studies for chronic spontaneous urticaria and advanced melanoma, addressing both symptom control and cancer treatment innovation.

• In chronic spontaneous urticaria, trials are testing whether new therapies can better reduce itching and hives in patients who do not respond well to standard antihistamines.
• For advanced melanoma, the focus is on evaluating combination treatment approaches that may strengthen the immune response against cancer.
• These studies aim to improve both day-to-day symptom relief and longer-term outcomes in challenging immune-mediated and oncologic conditions.

The work in this area highlights a practical interest in new therapy testing and better disease control for patients with complex skin-related conditions.

Research in nutritional and metabolic diseases at this hospital includes studies of non-alcoholic steatohepatitis, a liver disease linked to metabolic dysfunction and progressive fibrosis.

• The main goal is to assess whether emerging treatments can help resolve liver inflammation and slow or reverse fibrosis.
• Investigators are also paying attention to the longer-term safety of treatment, which is important for chronic liver disease care.
• This area of research supports better understanding of how to manage a condition that can lead to serious liver complications if left untreated.

Overall, the studies here are directed toward improving liver health through more effective and better-tolerated treatment options.